{"id":1021178,"date":"2026-11-16T07:04:15","date_gmt":"2026-11-16T12:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/"},"modified":"2026-11-16T07:04:15","modified_gmt":"2026-11-16T12:04:15","slug":"faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/","title":{"rendered":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer<\/b><\/p>\n<p><i>Faeth will sponsor and conduct a Phase 1b\/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant<\/i><\/p>\n<p><i>Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for use in the study<\/i><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nFaeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+\/HER2-) advanced breast cancer.<\/p>\n<p>\nUnder the terms of the agreement, Faeth will sponsor and conduct the Phase 1b\/2 study (Study FTH-PIK-101), and Roche will supply giredestrant for use in the study. Activation of the PI3K\/AKT\/mTOR pathway is a recognized mechanism of resistance to endocrine therapy in HR+\/HER2- breast cancer, providing the rationale for evaluating PIKTOR in combination with endocrine-directed agents.<\/p>\n<p>\n\u201cEndocrine therapy remains the backbone of treatment in HR+\/HER2- breast cancer, and resistance driven by the PI3K\/AKT\/mTOR pathway is one of the central problems in this setting,\u201d said Anand Parikh, Chief Executive Officer of Faeth Therapeutics. \u201cWe believe PIKTOR\u2019s multi-node approach to this pathway is well suited to patients whose disease has progressed on prior endocrine therapy, and this study will allow us to evaluate that approach in combination with giredestrant and potentially CDK4\/6 regimens.\u201d<\/p>\n<p><b>About PIKTOR<\/b><\/p>\n<p>\nPIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1\/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K\/AKT\/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), for which Faeth reported preliminary topline results on November 9, 2026. PIKTOR is also being evaluated in a Phase 1b\/2 trial in HR+\/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.<\/p>\n<p><b>About Faeth Therapeutics<\/b><\/p>\n<p>\nFaeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company\u2019s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.faeththerapeutics.com&amp;esheet=54641213&amp;newsitemid=20261116192980&amp;lan=en-US&amp;anchor=www.faeththerapeutics.com&amp;index=1&amp;md5=ed8581c66436fef1332d5db0d4b4952f\">www.faeththerapeutics.com<\/a> and follow the Company on LinkedIn.<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201con track\u201d and similar expressions, although not all forward-looking statements contain these words. These statements include, but are not limited to, statements regarding: the clinical trial collaboration and supply agreement with Roche and the anticipated benefits thereof; the planned study of PIKTOR in combination with giredestrant, including its design and conduct; the supply of giredestrant for the study; the Company\u2019s expectations regarding its pipeline and development plans, including the Phase 2 trial of PIKTOR in advanced endometrial cancer and the Phase 1b\/2 trial of PIKTOR in HR+\/HER2- advanced breast cancer and the anticipated timing of interim data; and the potential therapeutic benefits, tolerability profile and differentiation of PIKTOR.<\/p>\n<p>\nForward-looking statements are based on management\u2019s current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company\u2019s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to clinical development and the conduct, timing and results of clinical trials; risks related to reliance on third parties for the supply of investigational agents used in combination studies; the Company\u2019s need for additional financing; its limited operating history and history of operating losses; the Company\u2019s ability to satisfy applicable Nasdaq listing requirements and to maintain the listing of its common stock; and the other risks and uncertainties described under the headings \u201cRisk Factors\u201d and \u201cSummary of Risk Factors\u201d in the Company\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 30, 2026, its Quarterly Report on Form 10-Q filed with the SEC on November 3, 2026, and its definitive proxy statement filed with the SEC on April 27, 2026, as well as in the Company\u2019s subsequent filings. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261116192980\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261116192980\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Matthew Biegler, SVP, Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:matt@faeththerapeutics.com\">matt@faeththerapeutics.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Patrick Schmidt, Consort Partners<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:faeththerapeutics@consortpartners.com\">faeththerapeutics@consortpartners.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Texas United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Oncology General Health Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261116192980\/en\/2971029\/3\/Faeth_Therapeutics_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer Faeth will sponsor and conduct a Phase 1b\/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for use in the study AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021178","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer Faeth will sponsor and conduct a Phase 1b\/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for use in the study AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the &hellip; Continue reading &quot;Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T12:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\\\/HER2- Advanced Breast Cancer\",\"datePublished\":\"2026-11-16T12:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/\"},\"wordCount\":976,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/\",\"name\":\"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\\\/HER2- Advanced Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-16T12:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\\\/HER2- Advanced Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/","og_locale":"en_US","og_type":"article","og_title":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer - Market Newsdesk","og_description":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer Faeth will sponsor and conduct a Phase 1b\/2 study evaluating PIKTOR, its investigational all-oral combination of serabelisib and sapanisertib, in combination with the investigational medicine giredestrant Faeth retains all rights to PIKTOR; under the agreement, Roche will supply giredestrant for use in the study AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211; Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the &hellip; Continue reading \"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T12:04:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer","datePublished":"2026-11-16T12:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/"},"wordCount":976,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/","name":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-16T12:04:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261116192980r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluate-piktor-in-combination-with-a-selective-estrogen-receptor-degrader-in-hr-her2-advanced-breast-can\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+\/HER2- Advanced Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021178"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021178\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}